Key Drivers
- Strong liquidity
- Severe cash burn
- Negative margins
AIAI Summary
ALMS has shifted from a cash‑constrained R&D long‑shot to a funded, event‑driven bet where Phase‑3 envudeucitinib topline and timely, favorable NDA execution will primarily determine value—if full data, constructive FDA feedback, and early payer/launch traction materialize the current valuation can be justified, but constrained labeling, slower uptake, or approval setbacks would likely force further dilutive financings and sharply compress upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Severe cash burn
- •Negative margins
ALMS has healthy liquidity and low leverage but faces severe profitability and cash‑flow stress from heavy R&D/opex, low revenue productivity, and an outsized market valuation.
Price Behavior
Key Price Behavior Insights:
- •Below moving average
- •Near support test
- •~10% downtrend
Stock is in a modest short-term downtrend last month—down ~10% to $25.09, trading below the last month's average of $27.31 and sitting at near-term support around $24.80–$25.00, where a break would signal further downside while $29.50–$30.00 is nearby resistance.
~19% intraperiod range from $29.98 to $24.81 with a ~10% decline over the month
Sentiment & News
Key News Insights:
- •Positive Phase 3
- •Late-breaker AAD
- •New institutional stake
Alumis (ALMS) is showing clinical momentum for envudeucitinib with positive Phase 3 topline psoriasis results, upcoming high-profile scientific and investor presentations, and modest new institutional buying.
These developments should boost investor interest and visibility, potentially supporting the stock as clinical data are presented and discussed
Similar Companies in Healthcare
Other companies in the same sector with AI ratings